Combined thrombophilia according to hematological consultation data: 615.071

Abstract

Introduction. The diagnostic significance of homozygous mutation of FV Leiden and FII clotting factor genes, as well as their heterozygous polymorphism in combination with the markers of the primary antiphospholipid syndrome as predictors of thrombosis, remains ambiguous.

Aim: to present clinical cases of combined thrombophilia revealed during outpatient hematology counseling. Materials and methods. In the haematologist database from January 2012 to April 2017, we found 891 patients (837 women and 54 men) who were examined and consulted for thrombophilia and/or presence of active factors of thrombogenic risk.

Results. Combined thrombophilia was identified in 7 (0.8%) of 891 patients or in 7 (2.8%) of 246 patients with thrombogenic risk factors. In 4 cases — 2 men (44 and 28 years) and 2 women (29 and 33 years old) had a diagnosis due to severe and/or re- current venous and arterial thromboembolism and 3 women (27, 36 and 39 years) had a diagnosis due to fetal loss syndrome.

Conclusion. The observations confirm the practicability of researching for combined thrombophilia in case of recurrent throm- bosis for the choice of optimal anticoagulant therapy.

REFERENCES

1. Rosendorff A., Dorfman D. M. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med. 2007;131(6):866– 71.

2. Kabukcu S., Keskin N., Keskin A., Atalay E. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylenetetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey. Clin Appl Thromb Hemost. 2007;13(2):166–71.

3. Momot A. P., Tsyvkina L. P., Taranenko I. A. et al. Modern methods of recognition of the state of thrombotic readiness: monograph. [Sovremennye metody raspoznavaniya sostoyaniya tromboticheskoj gotovnosti: monografiya]. Barnaul: Izd-vo AGU, 2011. 137 s (in Russ.).

4. Lijfering W. M., Middeldorp S., Veeger N. J. et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Cir- culation. 2010;121(15):1706–12.

5. CADTH Optimal Use Report. Canadian Agency for Drugs and Technologies in Health. Guidance on the use of factor V Leiden and prothrombin mutation testing in patients with a first unprovoked thromboembolic episode [Internet]. Ottawa: The Agency. 2015;4(1b):10 p. URL: www.cadth.ca/media/pdf/OP0517_Throm- bophilia_Recs_Report.pdf. [Accessed: 28.09.2018].

6. Stevens S. M., Woller S. C., Bauer K. A. et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–64.

7. Chaturvedi S., McCrae K.R. The antiphospholipid syndrome: still an enigma. Hematology Am Soc Hematol Educ Program. 2015;(2015):53–60.

8. Biggioggero M., Meroni P. L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9(5): A299–A304.

9. Picillo U., De Lucia D., Palatiello E. et al. Association of a primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol. 1998;25(6):1232–4.

10. Simantov R., Lo S. K., Salmon J. E. et al. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. Thromb Res. 1996;84(5):361–5.

Diz-Kucukkaya R., Demir K., Yenerel M. N. et al. Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia (Budap). 2002;32(1):73–7.

Schutt M., Kluter H., Wiedemann G. J., Richardt G. Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia. Z Kardiol. 2000;89(12):1067–71.

Combemale P., Amiral J., Estival J. L. et al. Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia. Eur J Dermatol. 2002;12(3):278–82.

Schütt M., Klüter H., Hagedorn-Greiwe M. et al. Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus. 1998;7(3):176–82.
Kaiser R., Barton J. L., Chang M. et al. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun. 2009;10(5):495–502.

Katzav A., Grigoriadis N. C., Ebert T. et al. Coagulopathy triggered autoimmunity: an experimental antiphospholipid syndrome in factor V Leiden mice. BMC Med. 2013;(11):92.
Sukhikh G. T., Filippov O. S., Belokrinitskaya T. A. et al. Prevention of venous thromboembolic complications in obstetrics and gynecology. Clinical recommendations (protocol). [Profilak- tika venoznyh tromboembolicheskih oslozhnenij v akusherstve i ginekologii. Klinicheskie rekomendacii (protokol)]. Moskva, 2014. 32 s (in Russ.).

Laboratory Tests and Interpretation of Results. In: Ferri’s Clinical Advisor [Ed. F.F. Ferri]. 1st edition. Elsevier Mosby, 2012. Section IV. URL: https://www.twirpx.com/file/1062814 [Accessed: 28.09.2018].

Momot A. P., Nikolaeva M. G. Thrombophilia in obstetric-gynecological practice. Prophylaxis with heparin. [Trombofilii v akushersko-ginekologicheskoj praktike. Geparinoprofilaktika]. Medicinskij sovet. 2017;(13):71–8 (in Russ.).

Kaandorp S.P, Goddijn M., van der Post J. A. et al. Aspirin plus Heparin or Aspirin Alone in Women with Recurrent Miscarriage. N Engl J Med. 2010;362(17):1586–96.
De Jong P. G., Kaandorp S., Di Nisio M. et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;(7): CD004734.

Gerosa M., Meroni P. L., Erkan D. Recognition and management of antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28(1):51– 9.
Mekaj Y. H., Mekaj A. Y., Duci S. B., Miftari E. I. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;24(11):967– 77.